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Abstract: We describe the clinical and pathologic findings of a
young man with a heterogeneous mediastinal tumor metastatic to
both lungs, and containing a predominant pattern of classic biphasic
pulmonary blastoma with elements of immature teratoma, semi-
noma, and embryonal carcinoma. Beta-human chorionic gonadotro-
pin and alpha-fetoprotein were elevated at presentation and re-
sponded to four cycles of bleomycin, etoposide, and cisplatin
although the tumor did not regress. The patient ultimately pro-
gressed through paclitaxel, ifosfamide, and cisplatin and tandem
autologous bone marrow transplants. Classic biphasic pulmonary
blastoma is a rare tumor of young adults. Surgery is the primary
treatment, but prognosis is poor and chemotherapy and radiation
have been used for unresectable disease. A discussion of pulmonary
blastoma and extragonadal germ cell tumors is presented.
Key Words: Pulmonary blastoma, Extragonadal germ cell tumor,
Mediastinal mass.
(J Thorac Oncol. 2008;3: 1185–1187)
A 36-year-old man with a 22 pack-year smoking historypresented with right chest pain. Radiograph showed early
right-sided pneumonia and symptoms resolved with antibiot-
ics. A radiograph for left-sided chest pain and dyspnea 5
months later showed a new 11  13 cm anterior mediastinal
mass compressing the left main pulmonary artery (Fig. 1).
Multiple bilateral pulmonary metastases were present. Needle
biopsy at another institution was interpreted as nonsmall cell
lung cancer. Positron emission tomography-computed to-
mography (CT) only 6 days later demonstrated interval en-
largement and a new pericardial effusion with tamponade by
echocardiogram. Urgent subxiphoid pericardial window
drained a large cytologically negative effusion and revealed
normal pericardium. Tumor location in the anterior medias-
tinum and rapid progression called the initial diagnosis into
question. A thoracic pathologist (M.B.B.) interpreted the
outside biopsy as nondiagnostic. The mediastinal mass was
biopsied surgically when CT chest showed ongoing rapid
tumor growth (Fig. 2).
The biopsy specimen was roughly 60 to 70% classic
biphasic pulmonary blastoma (CBPB) with the very rare
finding of elements of teratoma, seminoma, and embryonal
carcinoma (Fig. 3). Serum beta-human chorionic gonadotro-
pin and alpha-fetoprotein (AFP) were 635 mIU/ml (0–4mIU/
liter) and 6,244 IUml (0.5–5 IU/ml), respectively. The germ
cell elements responded to two cycles of bleomycin, etopo-
side, and cisplatin; symptoms resolved, beta-human chorionic
gonadotropin fell to seven, AFP fell to 560, and CT showed
slight improvement. After four cycles, CT showed slight
enlargement of the mediastinal primary with stable tumor
markers. Radiotherapy (25 Gy in 10 fractions) was given for
local control followed by three cycles of salvage paclitaxel,
ifosfamide, and cisplatin complicated by grade 4 neutropenia,
Staphylococcus aureus bacteremia, and scrotal candidiasis.
The extent and location of the mass precluded surgical salvage.
Tandem autologous bone marrow transplants with carboplatin/
etoposide conditioning were ineffective and the patient died with
progressive disease 466 days after diagnosis.
DISCUSSION
Pulmonary blastoma is a rare neoplasm composed of
immature mesenchyme and epithelium resembling fetal lung
first described by Barrett and Barnard in 1945 and thought to
account for 0.25 to 0.5% of all pulmonary neoplasms.1 About
200 cases have been reported in the ensuing 60 years. The
most common subtype, CBPB, is typically large, diagnosed
in early adulthood, and carries a poor prognosis. Of 24 cases
reported by the University of Southern California and the
Armed Forces Institute of Pathology, the mean age was 39
and the mean size was 10.1 cm (largest 27 cm).2 Treatment
included resection  adjuvant chemotherapy and/or radia-
tion. Ten of 23 patients recurred within 11 months, with
average postrecurrence survival of 11 months. Untreated
patients survived no longer than 2 months.
Bodner and Koss found p53 mutations in five of nine
BPBs,3 however, Holst et al. found only one p53 mutation in
seven BPBs.4 No K-ras mutations were seen in a total of 10
BPBs.5 -Catenin mutations were identified in five of five
morule-forming BPBs.6 This pattern contrasts that of most
bronchogenic carcinomas, in which K-ras mutations are com-
mon, and -catenin mutations are rare. The mutations described
could result in activation of aberrant transcription factor signal-
ing and may play a role in the aggressive clinical nature of
CBPB. They could also provide a target for novel therapies.
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In the most recent WHO classification of lung tumors in
2004, CBPB became a subtype of sarcomatoid carcinoma.
The other blastoma subtypes, well differentiated fetal adeno-
carcinoma and pleuro-pulmonary blastoma are now consid-
ered subtypes of adenocarcinoma and mesenchymal tumor
respectively.7
Extragonadal germ cell tumor was first described in the
1940s and accounts for 10 to 15% of adult anterior medias-
tinal tumors. Extragonadal germ cell tumors generally occur
in the midline in young men, are sensitive to platinum-based
chemotherapy and express oncofetal antigens. They are sub-
divided into seminomas and nonseminomatous germ cell
tumors with a roughly 5-fold nonseminoma predominance.
Mediastinal nonseminomas germ cell tumor are by default
classified as “poor prognosis” under the International Germ
Cell Cancer Collaborative Group classification. Germ cell
tumors universally have increased copy number of the short
arm of chromosome 12, a region containing several cell-cycle
regulatory genes.8
Reports of chemotherapy for CBPB are scant. Four cycles
of etoposide plus cis-platinumwere used byMiller et al.9 to treat
an AFP-secreting primary pulmonary germ cell tumor with
blastomatous differentiation. The subject of that report re-
curred 1 year after thoracotomy and died shortly thereafter.
Siegel et al.10 also used etoposide plus cis-platinum to treat a
pulmonary blastoma with germ cell differentiation with sur-
gical salvage for residual disease showing extensive necrosis
in germ cell elements without response in the blastomatous
portion. Novel targeted therapies may hold promise against
CBPB. Mulamalla et al.11 described a pulmonary blastoma
metastatic to the right kidney which responded to the oral
multikinase inhibitor sorafenib after multiple prior surgical
and chemotherapy treatments. The patient’s thoracic disease
did not respond to sorafenib despite partial response of the
renal metastasis raising the possibility of a second primary
lesion in the kidney. c-KIT expression has been reported in
BPB suggesting a potential rationale for study of tyrosine
kinase inhibitors directed at KIT.12 The -catenin signaling
pathway is known to regulate tumorigenesis in other solid
malignancies and is abnormal in CBPB. Small molecule
inhibitors of -catenin and its downstream signal transducers
are in early development.
CONCLUSIONS
CBPB is a rare malignancy whose optimal treatment is
unknown. Surgery should remain the therapy for choice for
resectable disease, but the role of adjuvant or neoadjuvant
chemotherapy and radiation is unclear. Chemotherapy seems
FIGURE 1. Computed tomography of the chest shows a 13
cm anterior mediastinal mass.
FIGURE 2. Computed tomography of the chest at the time
of surgical biopsy shows rapid progression in 19 days. Medi-
astinal tumor now measures 18.5 cm and compresses the
left pulmonary artery and the left mainstem bronchus.
FIGURE 3. Approximately 70% of the biopsy specimen
contained classic biphasic pulmonary blastoma (CBPB) with
malignant glands growing in tubules resembling fetal bron-
chioles (hematoxylin and eosin, 100). The remainder of
the specimen (not shown) contained teratoma (immature
mesenchymal stroma with abortive hair follicle develop-
ment), seminoma (positive for placental alkaline phospha-
tase), and embryonal carcinoma (high grade undifferenti-
ated cells positive for CD30 and cytokeratin).
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appropriate for metastatic disease, especially for patients with
mixed histologies and if resection could be contemplated for
responding disease. The best available evidence supporting
the use of specific treatments still exists in the form of case
reports and small retrospective case series. Better character-
ization of molecular lesions in CBPB may lead to application
of targeted agents with the potential to improve responses.
Suspected diagnoses of CBPB should be reviewed with an
experienced lung pathologist and molecular diagnostics to
guide therapy could be considered if available. The rarity of
this tumor precludes large randomized trials, but patients
should be considered for participation in appropriate phase
I/II trials.
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